Loading data for IPHA — first visit, this takes a few seconds.

Alert

Innate Pharma S.A. (IPHA)

NasdaqGS: IPHA · Real-Time Price · USD

2.09

+0.02 (0.97%)

At close: Aug 19, 2026, 8:00 PM

2.09

-1.42%

After-hours: 4:29 PM

0.97% (1D)

No data available

Bid	2.19
Market Cap	199.07M
Revenue (ttm)	9.01M
Net Income (ttm)	-49.18M
Beta	0.86
EPS (ttm)	-0.64
PE Ratio (ttm)	n/a
Forward PE	-3.36
P/B (ttm)	-7.89
P/S (ttm)	22.11
Earnings Date	Sep 17, 2026

Ask	2.18
Volume	17,399
Avg. Volume (20D)	151,122
Open	2.11
Previous Close	2.07
Day's Range	2.09 - 2.13
52-Week Range	1.17 - 2.71
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About IPHA

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a d...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Oct 17, 2019

Employees 164

Stock Exchange NasdaqGS

Ticker Symbol IPHA

Website https://www.innate-pharma.com

Full Company Profile

Financial Performance

In 2025, Innate Pharma S.A.'s revenue was 2.79M, a decrease of -77.92% compared to the previous year's 12.62M. Earnings were -49.18M, a decrease of -0.59%.

Financial Statements

Earnings Surprise

Innate Pharma S.A. has released their quarterly earnings on Apr 3, 2022:

Revenue of n/a misses estimates by $0, with NaN% YoY growth.

EPS of -0.16 exceeds estimates by 0.01, with -Infinity% YoY decline.

Next Earnings Release

Innate Pharma S.A. is scheduled to release its earnings on Sep 17, 2026, before market opens.
Analysts project revenue of ... Upgrade

News

2 days ago · GuruFocus.com

Innate Pharma SA (IPHA) (Q2 2026) Earnings Call Highlights: Strategic Partnerships and Pipeline ...

Innate Pharma secures $30M equity raise and $75M SOBI upfront payment, advancing IPH 4502 and lacutamab while positioning for key PACIFIC-9 readout.

4 days ago · Simply Wall St.

Swedish Orphan Biovitrum (OM:SOBI) Following Its Lacutamab Deal And The Undervalued Narrative

Why Swedish Orphan Biovitrum Stock Is Back In Focus Swedish Orphan Biovitrum (OM:SOBI) has drawn fresh attention after a new partnership with Innate Pharma to run the TELLOMAK-3 Phase 3 trial for lacu...

5 days ago · MarketBeat

Innate Pharma Secures €30M, Extends Cash Runway Into 2028

Innate Pharma (NASDAQ:IPHA) said it has raised €30 million in equity financing, providing funding to advance its strategic priorities, including the development of its lacutamab and IPH4502 programs a...

1 week ago · Pharmaceutical Technology

Sobi licenses Innate’s CTCL drug for up to $580m as it heads to Phase III

Innate is planning to begin a Phase III confirmatory trial on lacutamab as it vies for the drug’s accelerated approval in a rare subset of CTCL.

3 months ago · MarketBeat

Innate Pharma Q1 Earnings Call Highlights

Innate Pharma (NASDAQ:IPHA) said its first-quarter 2026 business update centered on three priority clinical assets: lacutamab in cutaneous T-cell lymphoma, the Nectin-4 antibody-drug conjugate IPH4502...

Page 1 of 2

Innate Pharma S.A. (IPHA)